Based on the Summit Therapeutics PLC stock forecast from 3 analysts, the average analyst target price for Summit Therapeutics PLC is USD 28.70 over the next 12 months. Summit Therapeutics PLC’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Summit Therapeutics PLC is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Summit Therapeutics PLC’s stock price was USD 19.00. Summit Therapeutics PLC’s stock price has changed by +3.77% over the past week, -5.14% over the past month and +874.36% over the last year.
No recent analyst target price found for Summit Therapeutics PLC
No recent average analyst rating found for Summit Therapeutics PLC
Company Overview Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. Read Less
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Iv...Read More
Frequently Asked Questions About Summit Therapeutics PLC (SMMT) Stock
Based on ratings from 3 analysts Summit Therapeutics PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 9 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on SMMT's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for SMMT is USD 28.70 over the next 12 months. The maximum analyst target price is USD 45 while the minimum anlayst target price is USD 14.
SMMT stock's Price/Earning ratio is 28.13.
Our analysis grades SMMT stock's Price / Earning ratio at F. This means that SMMT stock's Price/Earning ratio is above 78% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SMMT may be a overvalued for its sector.
The last closing price of SMMT's stock was USD 19.00.
The most recent market capitalization for SMMT is USD 13.50B.
Based on targets from 3 analysts, the average taret price for SMMT is projected at USD 28.70 over the next 12 months.
This means that SMMT's stock price may go up by +51.05% over the next 12 months.
We can't find any ETFs which contains Summit Therapeutics PLC's stock.
As per our most recent records Summit Therapeutics PLC has 105 Employees.
Summit Therapeutics PLC's registered address is 601 Brickell Key Drive, Miami, FL, United States, 33131.
You can get more information about it from Summit Therapeutics PLC's website at https://www.summittxinc.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Summit Therapeutics PLC (SMMT) Stock
Based on ratings from 3 analysts Summit Therapeutics PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 9 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on SMMT's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for SMMT is USD 28.70 over the next 12 months. The maximum analyst target price is USD 45 while the minimum anlayst target price is USD 14.
SMMT stock's Price/Earning ratio is 28.13.
Our analysis grades SMMT stock's Price / Earning ratio at F. This means that SMMT stock's Price/Earning ratio is above 78% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SMMT may be a overvalued for its sector.
The last closing price of SMMT's stock was USD 19.00.
The most recent market capitalization for SMMT is USD 13.50B.
Based on targets from 3 analysts, the average taret price for SMMT is projected at USD 28.70 over the next 12 months.
This means that SMMT's stock price may go up by +51.05% over the next 12 months.
We can't find any ETFs which contains Summit Therapeutics PLC's stock.
As per our most recent records Summit Therapeutics PLC has 105 Employees.
Summit Therapeutics PLC's registered address is 601 Brickell Key Drive, Miami, FL, United States, 33131.
You can get more information about it from Summit Therapeutics PLC's website at https://www.summittxinc.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SMMT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
